nivolumab + paclitaxel

Nivolumab + paclitaxel is a combination therapy used primarily in oncology, combining an immune checkpoint inhibitor (nivolumab) with a cytotoxic chemotherapeutic agent (paclitaxel). Nivolumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands expressed by tumor cells. This blockade enhances T-cell mediated immune responses against cancer cells. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization, leading to apoptosis of rapidly dividing tumor cells. The combination has been investigated in several cancers including advanced gastric cancer, muscle-invasive bladder cancer, and non-small cell lung cancer as first-line or second-line therapy[4][5][8]. Nivolumab was developed by Bristol Myers Squibb; paclitaxel was originally developed from natural sources and commercialized by Bristol Myers Squibb.

Other names

nab-paclitaxel